DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

INTRODUCING: CHINA IN DEPTH

Assess commercial opportunities and optimize your strategy in China

China represents a $140 billion pharmaceutical market—the second largest in the world—with rapid growth projected in the years to come. Recently, national insurance coverage has been broadened and regulatory pathways somewhat streamlined, but enormous differences between urban and rural geographies remain, as does a lack of overall market transparency. China In Depth solution, developed by DRG with 15+ years of industry experience with the Chinese pharmaceutical market, provides comprehensive data and insights to help your business succeed in the lucrative Chinese pharmaceutical market.

Quantify
Accurately quantify market potential for your pipeline assets in China
Understand
Understand the commercial impact of new brands, generics and key China market events
Strategize
Optimize your clinical development and long-term strategies in China
DRG offers a comprehensive overview of the healthcare market in China through:
  • World-class epidemiology, including rural and urban populations
  • Keen insight into the complex access and reimbursement environment
  • Deeper understanding of current treatment paradigms including interviews with Chinese physicians
  • In-depth early stage and late stage pipeline coverage
  • 10-year, annualized, drug-level forecasts supported by detailed primary and secondary research
Featuring broad, deep and geographically diverse primary market research including
5 THOUGHT-LEADING PHYSICIAN INTERVIEWS and 50 PHYSICIAN SURVEYS per indication
On the basis of China’s epidemiology landscape, clinical unmet needs, and largest commercial opportunities, DRG has prioritized the following indications to cover in 2019:
Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Rheumatoid Arthritis, Non-Alcoholic Fatty Liver Disease (NASH), Multiple Sclerosis, Type 2 Diabetes, Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer